Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.38 Insider Own47.39% Shs Outstand138.14M Perf Week10.38%
Market Cap804.11M Forward P/E- EPS next Y-0.43 Insider Trans0.00% Shs Float86.51M Perf Month18.98%
Income-64.49M PEG- EPS next Q-0.10 Inst Own38.75% Short Float10.01% Perf Quarter-8.43%
Sales0.00M P/S- EPS this Y-24.68% Inst Trans2.44% Short Ratio4.91 Perf Half Y13.72%
Book/sh0.88 P/B5.54 EPS next Y-4.51% ROA-44.84% Short Interest8.66M Perf Year64.65%
Cash/sh0.87 P/C5.62 EPS next 5Y- ROE-58.59% 52W Range2.97 - 5.70 Perf YTD4.04%
Dividend Est.- P/FCF- EPS past 5Y29.09% ROI-43.49% 52W High-14.21% Beta1.01
Dividend TTM- Quick Ratio14.90 Sales past 5Y-20.00% Gross Margin- 52W Low64.65% ATR (14)0.30
Dividend Ex-Date- Current Ratio14.90 EPS Y/Y TTM-42.50% Oper. Margin0.00% RSI (14)62.73 Volatility5.54% 8.05%
Employees37 Debt/Eq0.22 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price10.71
Option/ShortYes / Yes LT Debt/Eq0.22 EPS Q/Q-61.22% Payout- Rel Volume1.08 Prev Close5.07
Sales Surprise- EPS Surprise-11.56% Sales Q/Q- EarningsMay 09 AMC Avg Volume1.76M Price4.89
SMA2016.94% SMA5012.66% SMA20012.13% Trades Volume1,902,813 Change-3.55%
Date Action Analyst Rating Change Price Target Change
Feb-15-24Initiated JMP Securities Mkt Outperform $8
Nov-07-23Initiated Guggenheim Buy $7
May-16-23Upgrade Jefferies Hold → Buy $2 → $4
Mar-31-23Downgrade Jefferies Buy → Hold $2
Mar-16-21Initiated Piper Sandler Overweight $7
Mar-15-21Initiated Oppenheimer Outperform $4
Jun-13-19Reiterated H.C. Wainwright Buy $22 → $6
Jun-13-19Downgrade Ladenburg Thalmann Buy → Neutral $21 → $3
Jun-13-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Aug-13-18Resumed ROTH Capital Neutral $12
Jun-29-24 08:35PM
Jun-28-24 08:50AM
Jun-26-24 07:41AM
08:05PM Loading…
Jun-25-24 08:05PM
Jun-19-24 09:00AM
Jun-11-24 06:00AM
May-29-24 08:05AM
May-21-24 08:20AM
May-19-24 12:15PM
May-16-24 04:05PM
May-09-24 10:55PM
May-07-24 04:05PM
08:05AM Loading…
Apr-08-24 08:05AM
Mar-22-24 04:05PM
Mar-07-24 10:54PM
Mar-06-24 04:05PM
Feb-02-24 08:05AM
Jan-31-24 08:05AM
Dec-30-23 03:01PM
Dec-21-23 08:05AM
Dec-20-23 08:05AM
Dec-15-23 04:05PM
Nov-21-23 08:05AM
Nov-09-23 04:05PM
Nov-08-23 04:05PM
Oct-06-23 04:05PM
07:29PM Loading…
Sep-27-23 07:29PM
Sep-17-23 10:54AM
Sep-12-23 09:12AM
Sep-05-23 04:05PM
Aug-10-23 04:05PM
Aug-04-23 04:05PM
Jul-13-23 07:00AM
Jun-26-23 04:05PM
Jun-02-23 08:05AM
May-28-23 08:26AM
May-16-23 12:32PM
May-15-23 08:05AM
May-05-23 04:05PM
Apr-03-23 07:33AM
Mar-31-23 04:05PM
Mar-30-23 04:05PM
Mar-20-23 06:35AM
Mar-17-23 06:47AM
Mar-16-23 06:51AM
Mar-15-23 06:44AM
Mar-13-23 06:32AM
Mar-10-23 07:04AM
Mar-09-23 06:33AM
Mar-08-23 06:30AM
Mar-07-23 06:34AM
Mar-06-23 04:05PM
Mar-03-23 06:38AM
Mar-02-23 06:44AM
Mar-01-23 06:01AM
Feb-28-23 04:05PM
Feb-27-23 06:50AM
Feb-23-23 07:21AM
Feb-22-23 06:56AM
Feb-21-23 07:35AM
Feb-17-23 06:27AM
Feb-16-23 07:28AM
Feb-15-23 07:01AM
Feb-14-23 08:05AM
Feb-13-23 07:30AM
Feb-10-23 06:42AM
Feb-09-23 06:51AM
Feb-08-23 06:45AM
Feb-07-23 06:46AM
Feb-06-23 06:56AM
Feb-03-23 06:32AM
Feb-02-23 06:43AM
Feb-01-23 06:14AM
Jan-31-23 06:50AM
Jan-30-23 06:42AM
Jan-27-23 03:47PM
Jan-26-23 06:44AM
Jan-25-23 06:39AM
Jan-24-23 06:48AM
Jan-23-23 06:58AM
Jan-20-23 08:05AM
Jan-19-23 06:43AM
Jan-18-23 06:28AM
Jan-17-23 06:27AM
Jan-13-23 06:56AM
Jan-12-23 06:50AM
Jan-11-23 06:53AM
Jan-09-23 06:31AM
Jan-06-23 06:49AM
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Elam Nevan CDirectorDec 28 '23Option Exercise1.3053,75869,722116,343Dec 29 04:33 PM
Elam Nevan CDirectorDec 28 '23Sale4.7193,843442,29122,500Dec 29 04:33 PM
Pauls MatthewCHIEF EXECUTIVE OFFICERDec 28 '23Sale4.7184,000395,9001,302,674Dec 29 04:35 PM
Lowrance David LCHIEF FINANCIAL OFFICERDec 28 '23Sale4.7110,00047,131342,355Dec 29 04:34 PM
Hawkins Richard JDirectorDec 11 '23Option Exercise0.8210,8418,89012,741Dec 12 06:09 PM
Elam Nevan CDirectorDec 11 '23Option Exercise0.8210,8418,89040,085Dec 12 06:08 PM
Chang Carmen10% OwnerJul 17 '23Buy3.00333,333999,99924,471,264Jul 19 07:07 PM
Behbahani Ali10% OwnerJul 17 '23Buy3.00333,333999,99924,471,264Jul 19 07:06 PM
BASKETT FOREST10% OwnerJul 17 '23Buy3.00333,333999,99924,471,264Jul 19 07:05 PM
Growth Equity Opportunities 1710% OwnerJul 17 '23Buy3.00333,333999,99924,471,264Jul 19 07:04 PM
Yang Rick10% OwnerJul 17 '23Buy3.00333,333999,99924,471,264Jul 19 07:13 PM
SANDELL SCOTT D10% OwnerJul 17 '23Buy3.00333,333999,99924,471,264Jul 19 07:11 PM
Walker Paul Edward10% OwnerJul 17 '23Buy3.00333,333999,99924,471,264Jul 19 07:12 PM
Mathers Edward T10% OwnerJul 17 '23Buy3.00333,333999,99924,471,264Jul 19 07:10 PM
Makhzoumi Mohamad10% OwnerJul 17 '23Buy3.00333,333999,99924,471,264Jul 19 07:09 PM
Florence Anthony A. Jr.10% OwnerJul 17 '23Buy3.00333,333999,99924,471,264Jul 19 07:08 PM